Skip to main content
Premium Trial:

Request an Annual Quote

Austrian Lab Accredited for NGS-based HLA Testing

NEW YORK (GenomeWeb News) – The Red Cross Blood Transfusion Service of Upper Austria said today it has been accredited by the European Federation for Immunogenetics for the use of human leukocyte antigen tests based on next-generation sequencing on Roche's GS Junior system.

The method provides more precise and rapid tissue-typing and donor selection for stem cell transplants, the laboratory said. The HLA testing had been use only for research, but will now be available as "a standard routine diagnostic procedure," it added.

"Worldwide, around 50,000 people a year urgently require a stem cell transplant, and the chances of finding an allogeneic stem cell donor are about one in 500,000" Thomas Schinecker, Head of Roche Sequencing Solutions, said in a statement. "This accreditation is an example of how the potential of next-generation sequencing can be successfully translated from research into medicine and made widely available to patients in areas of high medical need."

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.